Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.80 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.80 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.80 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.80 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.80 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.80 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.80 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.80 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2223535 | 0.91 | HDAC6 (0.84) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL10050234 | 0.90 | HDAC6 (0.82) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| Ricolinostat SCHEMBL574580 | 0.89 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL10050271 | 0.88 | HDAC6 (0.81) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL6878041 | 0.88 | HDAC6 (0.79) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL21707466 | 0.88 | HDAC6 (0.98) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL28411972 | 0.88 | HDAC6 (0.78) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL26079021 | 0.87 | HDAC6 (0.79) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL22014243 | 0.86 | HDAC6 (0.76) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL28408662 | 0.85 | HDAC6 (0.74) | HDAC6HDAC3HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-12-08 | — | — | US | claimed |
| WO-2011091213-A2 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-07-28 | — | — | WO | claimed |
| US-11617750-B2 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-10648038-B2 | Biomarkers to identify patients that will respond to treatment and treating such patients | ACETYLON PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200030325-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200030325-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| EP-3303304-B1 | METHODS OF MAKING PROTEIN DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-2839037-B1 | BIOMARKERS TO IDENTIFY PATIENTS THAT WILL RESPOND TO TREATMENT AND TREATING SUCH PATIENTS | ACETYLON PHARMACEUTICALS INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20170327895-A1 | Biomarkers To Identify Patients That Will Respond To Treatment And Treating Such Patients | ACETYLON PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170327895-A1 | Biomarkers To Identify Patients That Will Respond To Treatment And Treating Such Patients | ACETYLON PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170305866-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| WO-2013158984-A1 | BIOMARKERS TO IDENTIFY PATIENTS THAT WILL RESPOND TO TREATMENT AND TREATING SUCH PATIENTS | ACETYLON PHARMACEUTICALS, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| US-8394810-B2 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS (US) | 2013-03-12 | — | — | US | disclosed |
| WO-2013013113-A2 | HISTONE DEACETYLASE 6 SELECTIVE INHIBITORS FOR THE TREATMENT OF BONE DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20120190693-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2012-07-26 | — | — | US | disclosed |
| US-20120190693-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2012-07-26 | — | — | US | disclosed |
| US-8148526-B1 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148526-B1 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011091213-A2 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC3 3/4885HDAC1 2/4885 |
| US-20200030325-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC3 3/4885HDAC1 2/4885 |
| US-20170305866-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | HDAC1, HDAC6, HDAC9 | HDAC6 2/4885HDAC3 10/4885HDAC1 1/4885 |
| US-20120190693-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC3 3/4885HDAC1 2/4885 |
| US-11617750-B2 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC3 3/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.